Doctor Thomas Mondritzki
Bayer AG, Wuppertal (Germany)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Real-world evidence for patient phenotypes in heart failure with preserved ejection fraction
Event: ESC Congress 2024
Topic: Epidemiology, Prognosis, Outcome
Session: Heart failure therapy: new insights
Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor
Event: Heart Failure 2018
Topic: Experimental Heart Failure
Session: Chronic Heart Failure – Pathophysiology and Mechanisms
Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?
Event: ESC Congress 2016
Topic: Pharmacologic therapy
Session: Heart failure / Left ventricular dysfunction
